GemVax's "GV1001 for Benign Prostatic Hyperplasia Treatment Wins Best Paper Award at Korean Prostate Society"

[Asia Economy Reporter Hyunseok Yoo] GemVax & Kael (hereinafter GemVax) announced on the 9th that the paper on ‘GV1001,’ a drug under development for benign prostatic hyperplasia treatment, won the Best Paper Award at the 29th Annual Meeting of the Korean Society of Prostate.

The awarded paper is titled “Phase 2 Study on the Efficacy and Safety of GV1001 in Patients with Benign Prostatic Hyperplasia.” The research was conducted jointly by eight hospitals nationwide, including Professors Kyungseop Lee and Jiyong Ha from Keimyung University School of Medicine. The Best Paper Award is selected through a rigorous review of papers published in domestic and international journals within the last five years. This paper was published in the international journal BJUI (British Journal of Urology International).

According to the paper, the research team evaluated the efficacy and safety of GV1001 in 161 patients with benign prostatic hyperplasia through a phase 2 clinical trial. As a result, the group administered GV1001 showed statistically significant reductions in the International Prostate Symptom Score (IPSS) and prostate volume compared to the placebo control group. Notably, no clinically significant adverse effects or abnormal reactions were observed in the GV1001 group.

GemVax is currently conducting a domestic phase 3 clinical trial of GV1001 for benign prostatic hyperplasia at 23 institutions nationwide, including Keimyung University Dongsan Hospital.

Professor Kyungseop Lee, the principal investigator, said, “Following the previous award for the best academic achievement from the Korean Society of Prostate for research on the treatment effect of benign prostatic hyperplasia, I am pleased to receive the Best Paper Award as well. This award reaffirms the superior efficacy of GV1001 compared to existing drugs and the potential to overcome the shortcomings of benign prostatic hyperplasia treatments demonstrated through the phase 2 clinical trial.”

A GemVax official stated, “The results of the phase 2 clinical trial of GV1001 for benign prostatic hyperplasia have been evaluated as a step closer to new drug development as a drug that can complement the shortcomings of existing treatments. The ongoing phase 3 clinical trial has completed recruitment of 336 patients, and we expect to finish enrolling the target of 417 patients by July. We will do our best until all processes are successfully completed.”